Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?Zacks Investment Research • 03/20/25
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic AidBusiness Wire • 03/17/25
Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 EarningsZacks Investment Research • 03/06/25
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 GuidanceBusiness Wire • 03/06/25
Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025Business Wire • 02/27/25
Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/26/25
The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and AwarenessPRNewsWire • 01/21/25
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024Business Wire • 10/31/24
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It AttractiveSeeking Alpha • 10/25/24
Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 08/01/24